PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Hall, J.* ; Jeggo, P.A.* ; West, C.* ; Gomolka, M.* ; Quintens, R.* ; Badie, C.* ; Laurent, O.* ; Aerts, A.L.* ; Anastasov, N. ; Azimzadeh, O. ; Azizova, T.V.* ; Baatout, S.* ; Baselet, B.* ; Benotmane, M.A.* ; Blanchardon, E.* ; Guéguen, Y.* ; Haghdoost, S.* ; Harms-Ringhdahl, M.* ; Hess J. ; Kreuzer, M.* ; Laurier, D.* ; Macaeva, E.* ; Manning, G.* ; Pernot, E.* ; Ravanat, J.L.* ; Sabatier, L.* ; Tack, K.* ; Tapio, S. ; Zitzelsberger, H. ; Cardis, E.*

Ionizing radiation biomarkers in epidemiological studies – An update.

Mutat. Res.- Rev. Mutat. Res. 771, 59-84 (2017)
Postprint DOI PMC
Open Access Green
Recent epidemiology studies highlighted the detrimental health effects of exposure to low dose and low dose rate ionizing radiation (IR): nuclear industry workers studies have shown increased leukaemia and solid tumour risks following cumulative doses of <100 mSv and dose rates of <10 mGy per year; paediatric patients studies have reported increased leukaemia and brain tumours risks after doses of 30–60 mGy from computed tomography scans. Questions arise, however, about the impact of even lower doses and dose rates where classical epidemiological studies have limited power but where subsets within the large cohorts are expected to have an increased risk. Further progress requires integration of biomarkers or bioassays of individual exposure, effects and susceptibility to IR. The European DoReMi (Low Dose Research towards Multidisciplinary Integration) consortium previously reviewed biomarkers for potential use in IR epidemiological studies. Given the increased mechanistic understanding of responses to low dose radiation the current review provides an update covering technical advances and recent studies. A key issue identified is deciding which biomarkers to progress. A roadmap is provided for biomarker development from discovery to implementation and used to summarise the current status of proposed biomarkers for epidemiological studies. Most potential biomarkers remain at the discovery stage and for some there is sufficient evidence that further development is not warranted. One biomarker identified in the final stages of development and as a priority for further research is radiation specific mRNA transcript profiles.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
5.500
2.112
78
87
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Biomarkers ; Effects ; Exposure ; Individual Sensitivity ; Ionizing Radiation ; Molecular Epidemiology; Low-dose Radiation; Double-strand Breaks; Dna-damage Response; Papillary Thyroid Carcinomas; Gene-expression Profiles; Prolonged Occupational Radiation; Precision Epr Dosimetry; Blood Mononuclear-cells; Total-body Irradiation; Atomic-bomb Survivors
Sprache englisch
Veröffentlichungsjahr 2017
HGF-Berichtsjahr 2017
ISSN (print) / ISBN 1383-5742
e-ISSN 1388-2139
Zeitschrift Mutation Research / Reviews in Mutation Research
Quellenangaben Band: 771, Heft: , Seiten: 59-84 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Biological and Medical Imaging (IBMI)
Institute of Radiation Medicine (IRM)
Translational Metabolic Oncology (IDC-TMO)
Institute of Radiation Biology (ISB)
POF Topic(s) 30205 - Bioengineering and Digital Health
30203 - Molecular Targets and Therapies
30202 - Environmental Health
Forschungsfeld(er) Enabling and Novel Technologies
Radiation Sciences
PSP-Element(e) G-505500-001
G-501300-001
G-501000-001
G-500200-001
DOI 10.1016/j.mrrev.2017.01.001
WOS ID WOS:000399850400004
Scopus ID 85010755862
PubMed ID 28342453
Erfassungsdatum 2017-03-20
[➜Korrektur melden]